AstraZeneca Pharma India Limited has scheduled a meeting of its Board of Directors for Monday, August 10, 2026. The primary agenda item for this meeting is to consider and approve the Un-audited Financial Results of the Company for the quarter ended June 30, 2026 (Q1 FY2027).
The Company confirms that the 'Trading Window' remains closed for all Designated Persons under the Company's Code of Conduct for Prevention of Insider Trading. The closure period is from June 16, 2026 to August 12, 2026 (both days inclusive). This Code of Conduct is framed under the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.
The disclosure letter is addressed to both the National Stock Exchange of India Ltd. and BSE Limited, requesting them to take this information on record. The letter is signed by Tanya Sanish, who holds the positions of Company Secretary & Compliance Officer for AstraZeneca Pharma India Limited.